Sionna Therapeutics is cutting about 46 percent of its workforce after a Phase 2a trial of its cystic fibrosis add-on drug failed its main activity test. The Waltham company has not said how many people that is.
The board approved the reduction on Sept. 9 to focus on a different dual-drug program and make the company's available cash last longer. Sionna said it would keep the core clinical, scientific, regulatory, technical, and corporate staff for that work. It plans to start a Phase 2a trial of those two drugs in the first quarter of 2027.
The cut follows the PreciSION CF trial of SION-719 added to Trikafta, which missed its main measure of how well CFTR, a protein affected by cystic fibrosis, worked. Sionna is not advancing that drug as an add-on. Mike Cloonan, the company's president and chief executive, said a later analysis found factors that "may have blunted the impact of NBD1 stabilization," referring to the part of the protein the company is trying to stabilize.
The Form 8-K says Chief Business Officer Caroline Stark Beer was terminated without cause, effective Sept. 15, 2026. Sionna estimated about $6.4 million in restructuring charges and said the workforce cut was expected to be substantially complete by the end of the third quarter. That quarter ended Sept. 30. The company has not said whether the cut is finished.
Source: Sionna Therapeutics Form 8-K and Sept. 14, 2026 release (Exhibit 99.1), filed with the Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638d8k.htm https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638dex991.htm

